| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8278485 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Jun, 2027
(3 years from now) | |
| US8076515 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283380 | MDD US | Methods for treatment of parkinson's disease |
Mar, 2031
(6 years from now) | |
Xadago is owned by Mdd Us.
Xadago contains Safinamide Mesylate.
Xadago has a total of 3 drug patents out of which 0 drug patents have expired.
Xadago was authorised for market use on 21 March, 2017.
Xadago is available in tablet;oral dosage forms.
Xadago can be used as adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes.
Drug patent challenges can be filed against Xadago from 21 March, 2021.
The generics of Xadago are possible to be released after 21 March, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2022 |
Drugs and Companies using SAFINAMIDE MESYLATE ingredient
NCE-1 date: 21 March, 2021
Market Authorisation Date: 21 March, 2017
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
Dosage: TABLET;ORAL
XADAGO family patents
